Climb Bio (CLYM)

• Market cap: $320M
• 1 day: -6.56%
• 5 days: 33.52%
• 1 month: 56.67%
• 3 months: 135%
• 6 months: 230.99%
• Year to date: 25.33%
• 1 year: 144.79%
• 5 years: -70.44%
• 10 years: -70.44%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 18